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GCN2
ATF4Amino acid (AA) deprivation inmammalian cells activates a collection of signaling cascades known as the AA re-
sponse (AAR), which is characterized by transcriptional induction of stress-related genes, including FBJ murine
osteosarcoma viral oncogene homolog (cFOS). The present study established that the signaling mechanism un-
derlying the AA-dependent transcriptional regulation of the cFOS gene in HepG2 human hepatocellular carcino-
ma cells is independent of the classic GCN2-eIF2-ATF4 pathway. Instead, a RAS-RAF-MEK-ERK cascade mediates
AAR signaling to the cFOS gene. Increased cFOS transcription is observed from 4-24 h after AAR-activation,
exhibiting little or no overlapwith the rapid and transient increase triggered by thewell-known serum response.
Furthermore, serum is not required for the AA-responsiveness of the cFOS gene and no phosphorylation
of promoter-bound serum response factor (SRF) is observed. The ERK-phosphorylated transcription factor
E-twenty six-like (p-ELK1) is increased in its association with the cFOS promoter after activation of the AAR.
This research identiﬁed cFOS as a target of the AAR and further highlights the importance of AA-responsive
MAPK signaling in HepG2 cells.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Amino acid (AA) deprivation in mammalian cells activates several
signaling cascades collectively known as the AA response (AAR),
which is characterized by translational and transcriptional induction
of a wide-range of stress-related genes aimed at restoring cellular ho-
meostasis [1–3]. The protein kinase general control non-derepressible
2 (GCN2) is currently the onlywell characterized sensor for AA deﬁcien-
cy and the GCN2-eIF2-ATF4 pathway is the predominant AAR signaling
mechanism in mammalian cells. GCN2 senses AA limitation by binding
uncharged tRNAs, which activates its kinase activity resulting in phos-
phorylation of eIF2. The p-eIF2 leads to a slower ribosomal assembly
and a suppression of general translationwhile increasing the translation
of speciﬁc mRNA species containing short upstream opening reading, actinomycin D; ASNS, aspara-
FOS, FBJ murine osteosarcoma
ryotic initiation factor 2; ERK,
hyde 3-phosphate dehydroge-
histidinol; JNK, JUNN-terminal
mouse embryonic ﬁbroblasts;
TET, tetracycline
he National Institutes of Health,
try and Molecular Biology, Box
sville, FL 32610-0245. Tel.: +1frames [4,5]. Activating transcription factor 4 (ATF4) is a primary target
of this translational regulatory mechanism and an effector of many
genes involved in the AAR [6,7]. ATF4 induces transcription by binding
to C/EBP-ATF response elements (CARE) within hundreds of targeted
genes, including asparagine synthetase (ASNS) and C/EBP homology
protein (CHOP) [8,9]. However, emerging evidence suggests that
there are many AA-responsive genes that are regulated by GCN2-
independent mechanisms. This was demonstrated through a global ex-
pression array analysis of GCN2 knockout mouse embryonic ﬁbroblasts
(MEF) [10] and independently observed on a single gene basis for
FOXA2 and FOXA3 [11], cJUN [12], and EGR1 [10,13]. The present report
extends this list to include the FBJ murine osteosarcoma viral oncogene
homolog (cFOS) gene.
An expression array investigation performed inHepG2human hepa-
tocellular carcinoma cells showed that AAR activation increased expres-
sion of cFOS mRNA [14] and that observation was conﬁrmed in a
subsequent study [12]. cFOS is a transcription factor and proto-
oncogene involved in cellular proliferation and differentiation that
contains a basic leucine zipper (bZIP) region, which facilitates DNA
binding and dimerization with other bZIP proteins [15–17]. cFOS
associates with the known pro-apoptotic factor CHOP [18], a well-
characterized target gene for the AAR [reviewed in 1]. cFOS is a member
of a larger class of genes termed “immediate early response genes”
based on their rapid and transient induction following extracellular
stimulation by growth factors and stress [16,19,20]. Although the func-
tions of cFOS are diverse, context dependent, and not completely under-
stood [15], it is clear that elevated cFOS expression can contribute to
Table 1
qPCR Primers and shRNA Sequences (Human).
Primerswere obtained from Sigma-Aldrich and shRNA constructs from Open Biosystems/
Thermo Scientiﬁc.
qPCR Primers:
GAPDH mRNA Sense, TTGGTATCGTGGAAGGACTC
Anti-sense, ACAGTCTTCTGGGTGGCAGT
cFOS mRNA Sense, GGAGGAGGGAGCTGACTGATA
Anti-sense, GGCAATCTCGGTCTGCAA
cFOS hnRNA Sense, ATGGAGGTGATGGCAGACACTTTTAC
Anti-sense, TCTTATTCCTTTCCCTTCGGATTCTC
ASNS mRNA Sense, GCAGCTGAAAGAAGCCCAAGT
Anti-sense, TGTCTTCCATGCCAATTGCA
ATF4 mRNA Sense, GGGACAGATTGGATGTTGGAGA
Anti-sense, ACCCAACAGGGCATCCAAGT
GCN2 mRNA Sense, GAAATGGTAAACATCGGGCAAACTC
Anti-sense, TTCACAAGAGCCAGGAGAATCTTCAC
ERK1 mRNA Sense, CGCTTCCGCCATGAGAATGTC
Anti-sense, CAGGTCAGTCTCCATCAGGTCCTG
ERK2 mRNA Sense, CGTGTTGCAGATCCAGACCATGAT
Anti-sense, TGGACTTGGTGTAGCCCTTGGAA
ATF3 mRNA Sense, GAGCGGAGCCTGGAGCAAAA
Anti-sense, GGGGACGATGGCAGAAGCACT
CHOP mRNA Sense, CATCACCACACCTGAAAGCA
Anti-sense, TCAGCTGCCATCTCTGCA
EGR1 mRNA Sense, AGAAGGACAAGAAAGCAGACAAAAGTGT
Anti-sense, GGGGACGGGTAGGAAGAGAG
cJUN mRNA Sense, TTCTATGACGATGCCCTCAACGC
Anti-sense, GCTCTGTTTCAGGATCTTGGGGTTAC
CAT1 mRNA Sense, TCATCTGGAGGCAGCCCGAG
Anti-sense, CATCATGAGATAGACGTTCACGAAGATG
IL-8 mRNA Sense, TCTCTTGGCAGCCTTCCTGATTTC
Anti-sense, GGGGTGGAAAGGTTTGGAGTATGT
KRAS mRNA Sense, CTAGAACAGTAGACACAAAACAGG
Anti-sense, CGAACTAATGTATAGAAGGCATC
HRAS mRNA Sense, TACGGCATCCCCTACATCGAGAC
Anti-sense, CACCAACGTGTAGAAGGCATCCTC
NRAS mRNA Sense, GAGTTACGGGATTCCATTCATTGAAAC
Anti-sense, TGGCGTATTTCTCTTACCAGTGTGTAAAA
ELK1 mRNA Sense, CTGACCCCATCCCTGCTTCCTA
Anti-sense, GAAGTGAATGCTAGGAGGCAGCG
ChIP Primers:
P1 Forward: TTTCACCTCTGCCTGTGACAGGG,
Reverse: GGGGATTCGTGGAACTGGGC
P2 Forward: CCATCCCCGAAACCCCTCAT,
Reverse: GCGTGTCCTAATCTCGTGAGCATTT
P3 Forward: GTGGTTGAGCCCGTGACGTTTA,
Reverse: TCTTGGCTTCTCAGATGCTCGC
P4 Forward: GTAAGGCAGTTTCATTGATAAAAAGCGAG,
Reverse: CACTTGCTTGAAAGGGGGTTTGTTATA
P5 Forward: CCAACCTGCTGAAGGAGAAGGAAA,
Reverse: GATCAAGGGAAGCCACAGACATCTC
P6 Forward: GCATTGTGGTTTCTGGTTTCTCTAATACC,
Reverse: CCCACTTCCGCCCACTATAAACTG
Anti-sense shRNA:
shCtrl (non-silencing) CUUACUCUCGCCCAAGCGAGAG
shATF4 (TRIPZ) UAAACUUUCUGGGAGAUGG
shGCN2 (GIPZ) UCAUUGCAAUCUUCAUCCU
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trate the complexity of its functions, cFOS has also been linked to
tumor suppression in some circumstances [21].
Transcriptional regulation of the cFOS gene is induced by a wide va-
riety of stimuli that trigger mitogen-activated protein kinase (MAPK)
signal transduction pathways. For example, activation of the mitogen-
activated extracellular kinase (MEK)/extracellular-regulated kinase
(ERK) pathway is crucial for cFOS induction in response to growth fac-
tors,mitogens, and cell stress,most ofwhich trigger increased transcrip-
tion via a cluster of sequences in the cFOS promoter often referred to as
the serum response element (SRE) [16,19,20]. Two of the sequences
within the SRE region are the CArG element (CC-A/Tn-GG), known to
bind serum response factor (SRF), and the E-twenty six (ETS) motif
(GGA-A/T) that is bound by ternary complex factor (TCF) members,
such as (ETS)-like factor 1 (ELK1) [22,23]. The induction of the cFOS
gene triggered by the ERK pathway involves phosphorylation of consti-
tutively bound SRF and/or ELK1, which is associated with chromatin
remodeling and increased transcription [19,20,24,25]. One of the hall-
marks of the immediate early response genes is a rapid onset of tran-
scriptional activation that is of short duration. Typical of this group,
after exposure of the cells to stimulus, a high degree of cFOS transcrip-
tion occurs within 15 min and the return to near basal rate occurs
within 90 min [16,19].
Although GCN2-eIF2-ATF4 is the best characterized AAR signaling
pathway and the predominantmechanism for AA-responsive transcrip-
tional control inmammalian cells, a recent ChIP-sequencing analysis for
ATF4 binding sites did not identify functional ATF4-responsive genomic
elements associated with the cFOS gene [26]. The present study investi-
gatedGCN2-independent AAR target genes in HepG2 humanhepatocel-
lular carcinoma cells cultured in medium deﬁcient for the essential AA
histidine to activate the AAR. The results document that cFOS was
among a number of genes that are induced in a GCN2- and ATF4-
independent process following AA limitation. For cFOS in particular,
AA-responsive transcription was dependent on the RAS-RAF-MEK-ERK
arm of MAPK signaling. Association of the ERK-phosphorylated tran-
scription factor p-ELK1 with the cFOS promoter was increased after ac-
tivation of the AAR, whereas the abundance of total or phosphorylated
SRF was not increased. The latter result is consistent with additional
data distinguishing the induction by AA limitation from that of serum
replenishment. The results indicate that the ELK1 transcription
factor and ETS genomic sequences must be added to the list of
AA-responsive genomic signaling mechanisms that contribute to the
overall AAR program in mammalian cells. Furthermore, this work ex-
tends our understanding of the role that MAPK pathways play during
amino acid stress.
2. Materials and methods
2.1. Reagents
Actinomycin D (ActD) (#A1410), thapsigargin (TG) (#T9033), and
tetracycline (TET) (#T3258) were from Sigma-Aldrich Co. (St. Louis,
MO). All PCR primers used were obtained from Sigma-Aldrich and
are listed in Table 1. The siRNA siGENOME SMARTpool constructs for
non-targeting siRNA Pool #2 (siCtrl) (#D-001206-14-05), siH-RAS
(#M-004142-00-0005), siK-RAS (#M-005069-00-0005), siN-RAS
(#M-003919-00-0005), si-ERK1 (#L-003592-00-0005), and siERK2
(#L-003555-00-0005), siELK1 (#L-003885-00-0005) were purchased
from Dharmacon/Thermo Scientiﬁc. Transient siRNA transfections
with 25 nM for each siRAS member or 50 nM each for siERK1 +
siERK2 (a total of 100 nM) were performed in 12-well plates according
to the manufacturer’s protocol using DharmaFECT4 Transfection Re-
agent (T-2004-02) 48-72h prior to activating theAAR. The following in-
hibitors were diluted in dimethylsulfoxide. MEK inhibitor (PD98059,
#P215) and c-RAF inhibitor (GW5074, #G6416) were obtained from
Sigma-Aldrich. The p38 inhibitor (SB203580, #559389) was fromEMD Millipore and the JNK inhibitor (SP600125, #S1076) was from
Selleck Chemicals (Houston, TX).
2.2. Cell culture
HepG2 and aHepG2 subclone (C3A) humanhepatocellular carcinoma
cells, HC-04 immortalized human hepatocytes, U87 human glioblastoma
cells, and HEK293T human embryonic kidney cells were cultured in high
glucose (4.5 g/L) Dulbecco’s modiﬁed Eagle’s medium (DMEM, pH 7.4)
supplemented with 10% fetal bovine serum, 1X non-essential AAs,
2 mM glutamine, 100 μg/ml streptomycin sulfate, 100 units/ml penicillin
G, and 0.25 μg/ml amphotericin B in a 37 °C incubator with 100% humid-
ity and 5% CO2. For experimental treatment, cellswere plated at a density
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plates. For transient siRNA experiments, cells were plated at 0.25 x 106
per well in 12-well plates and incubated for 48-72 h prior to activating
the AAR. Complete DMEM medium plus serum was replenished 12 h
prior to initiating any experimental treatments to maintain a basal nutri-
tional state. Cells were then cultured in complete DMEMmedium or in
DMEM medium deﬁcient for L-histidine (“DMEM-His”) (obtained from
US Biologicals, #D9801-02) to activate the AAR. For a few experiments
(as indicated), the AAR was activated by incubation of the cells in com-
plete DMEM containing with 2 mM L-histidinol (HisOH), which blocks
the charging of histidine onto its cognate tRNA, thus mimicking histidine
deprivation without actually depleting cellular histidine levels [27]. For
stable knock down studies, HepG2 cells transduced with lentivirus con-
structswere plated at a density of 2.5 x 105 cells per 60mmdish topermit
shRNA expression and then treated with DMEM or DMEM-His at a simi-
lar conﬂuence as the cells in all other experiments. The HEK293T-ATF4
cell line (with tetracycline (TET)-inducible ATF4 expression) was a gift
from Dr. Tonis Ord [28], (Institute of Molecular and Cell Biology, Tartu
University, Tartu, Estonia). The HEK293T-ATF4 cells were stably
transfected at 5 μg/60 mm dish with a constitutively-active MEK1
(MEKCA) construct [29] or as a control, green ﬂuorescent protein
(GFP-pcDNA3.1), using a calcium phosphate protocol [30]. The cells to
be transfected were incubated with the plasmids overnight, washed
twice with PBS, replenished with complete DMEM/serum, and incubat-
ed for another 36 h prior to activation of the AAR.
2.3. Lentiviral preparation, transduction, and HepG2 clonal selection
The TRIPZ inducible non-silencing lentiviral shRNA control
(RHS4743) and shATF4 (RHS4696-99703331, clone ID: V2THS_132755)
plasmids and the GIPZ non-silencing lentiviral shRNA control
(RHS4346) and shGCN2 (RHS4430-101133792, clone ID: V3LHS_
350194) plasmids were obtained from Thermo Scientiﬁc/Open
Biosystems and the antisense RNA sequences are listed in Table 1. All
lentiviral plasmids were prepared according to the manufacturer’s
protocol and puriﬁed with the HiSpeed Plasmid Midi Kit (Qiagen,
12643). HEK293T-ATF4 cells were transiently transfected using the
Trans-Lentiviral shRNA Packaging Kit with calcium phosphate (Thermo
Scientiﬁc/Open Biosystems, TLP5912) according to the manufacturer’s
protocol. HepG2 cells were transduced with each viral preparation
according to the manufacturer’s protocol, except that the volume of
virus-containing supernatant was doubled and the volume of serum-
free medium was reduced accordingly. Greater than 50% transduction
efﬁciency was achieved as visualized by ﬂuorescent microscopy 48 h
after transduction. Puromycin dihydrochloride (Sigma-Aldrich, #P8833)
(2.5 μg/ml)was used for selection and limiting dilutionwas subsequently
used to select and expand clonal cell lines. TRIPZ transduced cells were
induced with 2.0 μg/ml doxycycline (DOX) (Sigma-Aldrich, D9891). The
clonal cell lines demonstrating the most efﬁcient knockdown were
characterized and used for further experimental analysis.
2.4. RNA isolation and quantitative real-time PCR (qPCR)
Total RNA was isolated from cells using TRIzol Reagent (Life Tech-
nologies, #15596018) according to the manufacturer’s protocol. RNA
samples were prepared from a minimum of three separate dishes for
each condition within an experiment and each experiment was repeat-
edwith independent batches of cells. The cDNAwas prepared using 1 μg
RNA per sample with the qScript cDNA Synthesis Kit (Quanta,
#95047-100) according to the manufacturer’s protocol. The quanti-
tative real-time PCR (qPCR) was performed with SYBR Green (Applied
Biosystems/life Technologies, #4309155) according to the manufac-
turer’s protocol and detected using a CFX Connect Real-Time System
(BioRad, #185-5201) with the following protocol: 95 °C for 10 min, 95 °C
for 15 sec, 60 °C for 60 sec, repeat steps 2-3 for 39 more cycles. This
reaction was followed by denaturing at 95 °C for 15 sec and thenheating from 55 °C to 98 °C in 0.5 °C increments for 5 sec each to pro-
duce a melting curve to ensure that only a single product was obtained.
Where possible, the steady state RNA levels were measured using
primers from two adjoining exons that cross a large intron to minimize
the contribution of genomic DNA and the transcription activity was
measured using primers that cross an intron-exon boundary tomeasure
the short-lived hnRNA [31]. The PCR primers used are listed in Table 1.
2.5. Protein isolation and immunoblotting
After washing cells with PBS, whole cell protein was extracted by
lysing cells with RIPA buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl,
1 mM Na2EDTA, 0.5% sodium deoxycholate, 1.0% Triton X-100, and
0.1% sodium dodecyl sulfate) supplemented with Pierce Protease and
Phosphatase Inhibitor Mini Tablets (Thermo Scientiﬁc, #88668). Immu-
noblotting was performed as described previously [32]. The mouse
monoclonal anti-p-ERK (#sc-7383), rabbit polyclonal anti-total ERK1/
2 (#sc-94), and the rabbit polyclonal anti-cFOS antibodies were from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA) The rabbit anti-β-actin
polyclonal antibody (#A2066) from Sigma-Aldrich. The rabbit polyclon-
al anti-ATF4 (#ABE387) was from EMD Millipore. A goat anti-rabbit
IgG-HRP conjugate (BioRad, #170-6515) and a goat anti-mouse IgG-
HRP conjugate (Santa Cruz, #sc-2005)were used as the secondary anti-
bodies (BioRad, #170-6515). Bound secondary antibody was detected
using Pierce ECL Western Blotting Substrate (Thermo Scientiﬁc,
#32106) according to themanufacturer’s protocol followed by chemilu-
minescent imaging on autoradiography ﬁlm.
2.6. Chromatin immunoprecipitation (ChIP)
ChIP analysis was performed according to a previously published
protocol [32]. HepG2 cells were seeded at a density of 1.5 X 107 per
150 mm dish with DMEM medium and cultured for approximately
36 h, which includes a transfer to fresh DMEM/serum during the ﬁnal
12 h prior to treatment. Immunoprecipitation was performed with
one of the following antibodies. Rabbit anti-RNA Polymerase II poly-
clonal antibody (#sc-899), rabbit anti-serum response factor (SRF,
#sc-335), and, as a non-speciﬁc negative control, a normal rabbit IgG
(#sc-2027) purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). The total ELK1 (#9182) and S103 phospho-SRF (#4261) antibodies
were purchased from Cell Signaling, whereas the S383 phospho-ELK1
antibody was obtained from Abcam (Boston, MA, #32799).
Immunoprecipitated DNAwas analyzed with qPCR using primers listed
in Table 1. The ChIP results are presented as the ratio to input DNA and
are the averages of assays performed in triplicate.
2.7. Statistical analysis
The results obtained were analyzed using Student’s t-test (2-tailed)
and p values ≤ 0.05 were considered statistically signiﬁcant. All values
are expressed as themeans± standard deviation of at least triplicate as-
says to measure technical variation and typically multiple experiments
were performed with independent batches of cells to assess biological
reproducibility.
3. Results
3.1. GCN2-independent induction of AA-responsive genes
To test the hypothesis that someAAR target genes in HepG2 cells are
activated independently of GCN2, a clonal cell line was generated that
stably expresses shGCN2. Based on work in Gcn2 knockout mice, it ap-
pears that loss of the kinase does not cause major detrimental effects
in the absence of stress [33,34]. The growth properties andmorphology
of theHepG2-shGCN2 cells were similar to those of cells selected for ex-
pression of a control shRNA sequence (HepG2-shCtrl). Using
542 J. Shan et al. / Biochimica et Biophysica Acta 1853 (2015) 539–548information from an expression array analysis in HepG2 cells [14], sev-
eral genes were chosen to analyze the contribution of GCN2 after incu-
bation in DMEM lacking histidine (DMEM - His). As shown by the
examples in Fig. 1, with regard to GCN2-dependency, three categories
of genes were observed: 1) genes for which GCN2 knockdown had a
major negative effect (ASNS, CHOP, ATF4), 2) genes that were partially
affected (ATF3, CAT1), and 3) genes for which the loss of GCN2 had no
effect or were slightly enhanced in their AA responsiveness (IL-8,
EGR1, cJUN, cFOS). With regard to the latter group, cJUN was not unex-
pected in that previous studies had shown that its AAR induction was
independent of ATF4 [12]. The results shown in Fig. 1 extend that obser-
vation to also exclude GCN2 as a necessary step in cJUN activation.
Given the fundamental nature of cFOS in controlling cell growth and
its ability to function as an oncogene, it was chosen for further study.
3.2. Mechanisms of cFOS regulation in HepG2 cells during AA deprivation
The AAR-associated cFOS transcription activity, examined byqPCRof
heteronuclear RNA (hnRNA),was clearly increased by 4 h and reached a
maximum of about 15-fold by 8 h (Fig. 2A). Steady state mRNA also
increased by several fold within 4 h of histidine removal from the
medium, peaked at about 8 h, and then declined to a plateau of about
12- to 15-fold induction between 12 and 24 h (Fig. 2A). The increase
in cFOS protein was evident, but much less pronounced than the corre-
sponding mRNA content. The maintenance of an elevated steady state
mRNA at 24 h in the presence of a decline to the DMEM level for
transcription activity suggested that the cFOS mRNA may be stabilized
during the AAR. cFOS mRNA was measured by qPCR following incuba-
tion of cells in DMEM - His medium for 8 h and then transfer to
DMEM ± His in the presence of 5 μM actinomycin D to block further
mRNA synthesis (Fig. 2B). Amodest increase inmRNAhalf-life occurred
in response to AA limitation. It has been documented that HuR binding
to mRNA species during the AAR can lead to increased half-life [35,36].Fig. 1. AA responsive genes show a wide variation in their dependence on GCN2 in HepG2 hum
HepG2 clonal cell lines were generated that stably express either a control shRNA (shCtrl) or
DMEM deﬁcient for histidine (DMEM-His) for 8 h and then steady state mRNA levels for the in
was used as an internal control and results shown are the means ± SD of assays in triplicate.
the DMEM control.Thus, whereas mRNA stabilization was a contributing factor, the prima-
ry mechanism for increased cFOS expression during the AAR appeared
to be enhanced transcription.
To test the cell speciﬁcity of cFOS induction, a number of other cell
types were screened. cFOS transcriptional induction was also observed
to occur in the HepG2 subclone C3A cells (Fig. 2C), but the induction
was weaker than for the parental HepG2 cell line (Fig. 2A). The
American Type Culture Collection (ATCC) website describes C3A cells
as being selected to exhibit more hepatocyte-like properties than
parentalHepG2 cells. It is possible that themagnitude of the cFOS induc-
tion is related to transformation because non-transformed, immortal-
ized HC-04 human hepatocytes showed little or no induction (Fig. 2C).
In a transformed cell line from a different tissue, U87 human glioblasto-
ma cells, the AAR-induced increase in cFOS expression was similar in
magnitude to that observed in HepG2 cells, regardless of whether the
cells were incubated in histidine-free medium or in DMEM containing
2 mM of the histidine deprivation mimetic HisOH (Fig. 2D). There was
a temporal difference between the HepG2 and U87 cells in that the in-
duction in the U87 cells occurred within 1 h and was quite transient
(Fig. 2D). The rapid kinetics in the U87 cells is reminiscent of the
extensively-characterized “serum response” for cFOS [16,19]. Induction
of cFOS by growth factors, cytokines, and other extracellular signals can
be illustrated by the serum response, a rapid, but transient induction
triggered by refeeding of serum-starved cells or exposure to one of the
blood bornemessengers. This response is mediated byMEK-ERK signal-
ing and the increased transcription following serum treatment occurs
within minutes and lasts for only an hour or so. The serum response
should occur in control DMEM medium. Indeed, after the medium
change to DMEM ± His a small increase in cFOS mRNA at 1 h was
observed in the DMEM incubated U87 cells (Fig. 2D). However, the
AAR induction was clearly superimposed on the serum effect and
much greater inmagnitude. To further investigate the possible relation-
ship between the serum response and the AAR, the regulation of cFOS inan hepatocellular carcinoma cells. To survey AAR target genes for dependence on GCN2,
an shRNA speciﬁc for GCN2 (shGCN2). The cells were incubated in complete DMEM or
dicated genes were measured by qPCR. GAPDH mRNA, which is not affected by the AAR,
An asterisk indicates that the DMEM - His value is signiﬁcantly different (p ≤ 0.05) than
Fig. 2. Mechanism of cFOS regulation in HepG2 cells during the AAR. (Panel A) HepG2
human hepatocellular carcinoma cells were incubated in complete DMEM or DMEM deﬁ-
cient for histidine (DMEM-His) for 0-24 hours as indicated and cFOS transcription activity
as measured by hnRNA or cFOS steady state mRNA were assayed by qPCR. cFOS protein
levels were assessed by immunoblotting. (Panel B) Cells were incubated in medium
deﬁcient for histidine (DMEM-His) for 8 h and then transferred to complete DMEM or
DMEM - His for an additional 2 h, both containing 5 μM actinomycin D (ActD). cFOS
mRNA was measured by qPCR and data were plotted as the logarithm of mRNA content
versus time following transfer to ActD containing medium. (Panel C) The HepG2 sub-
clone, HepG2-C3A, and non-transformed, immortalized human hepatocytes (HC-04)
were incubated in complete DMEM or DMEM - His for 8 h and cFOS steady state mRNA
was measured by qPCR. An asterisk indicates that the DMEM - His value is signiﬁcantly
different (p ≤ 0.05) than the DMEM control. (Panel D) U87 human glioblastoma cells
were incubated in complete DMEM, DMEM - His, or complete DMEM ± 2 mM HisOH
for 0-12 h as indicated and then cFOS steady state mRNA was measured by qPCR. In all
panels, GAPDHmRNA, which is not affected by the AAR, was used as an internal control
and results shown are the means ± SD of at least triplicate assays.
Fig. 3. The effect of serum on AAR regulation of cFOS. (Panel A) HepG2 cells were incubat-
ed in DMEM± His for 0-4 h as indicated and cFOS steady state mRNA was measured by
qPCR. (Panel B) Following overnight serum starvation, HepG2 cells were transferred to
freshmedium either lacking 10% FBS (- serum) or containing 10% FBS (+ serum), as indi-
cated. The cells in both serum treatment groups were incubated in DMEM±2mMHisOH
for 6 h and then cFOS steady state mRNAwasmeasured by qPCR. For both panels, GAPDH
mRNA,which is not affected by the AAR,was used as an internal control and results shown
are the means ± SD of assays in triplicate. An asterisk indicates that the values are signif-
icantly different (p ≤ 0.05).
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DMEM± His containing 10% FBS (Fig. 3A). A transient serum response
of about 2-fold peaked at 1 h and returned to the basal state by 2 h in the
cells incubated in control DMEMmedium. Removing histidine from the
medium did not further enhance the induction at 1 h. In contrast, the
AAR-dependent induction appeared to begin between 2 and 4 h(Fig. 3A), consistent with the response shown in Fig. 2A. To further
establish that theAAR-dependent induction of cFOS inHepG2 cells is in-
dependent of serum, HepG2 cells were incubated overnight (16 h) in
serum-freemedium and then treated for 6 hwithHisOH in the presence
or absence of serum. The results illustrate that the AA-responsiveness of
the cFOS gene was not dependent on serum; in fact, the induction was
slightly suppressed by the presence of serum (Fig. 3B).
3.3. cFOS AAR regulation is GCN2-ATF4 independent
GCN2 is the only known sensor for AA deﬁciency in mammalian
cells, and given that the GCN2-eIF2-ATF4 pathway is considered the pri-
mary AAR pathway [2,3], its relationship to cFOS induction was exam-
ined. Consistent with the data of Fig. 1, in HepG2-shGCN2 cells, the
GCN2 mRNA levels were effectively knocked down by approximately
80% compared to the HepG2-shCtrl or parental HepG2 cells (Fig. 4A).
As assayed by immunoblotting, AAR associated ATF4 protein induction
was largely abolished in the HepG2-shGCN2 cells (data not shown). De-
spite the efﬁcient knock down of GCN2, cFOS induction was unaffected
following activation of the AAR (Fig. 4A). As a further test for the lack of
a role for the GCN2-eIF2-ATF4 pathway, a HepG2-shATF4 clonal cell
line, expressing a doxycycline (DOX) inducible shRNA against ATF4
was tested (Fig. 4B). After DOX treatment, therewas a signiﬁcant reduc-
tion in both ATF4 and ASNS mRNA levels. In contrast, no effect on cFOS
Fig. 4. AAR regulation of cFOS is GCN2- and ATF4-independent. (Panel A) Parental HepG2
cells, and two HepG2-derived clonal cell lines, one stably expressing a non-silencing
shRNA (shCtrl) and another expressing shRNA against GCN2 (shGCN2) were incubated
in DMEM ± His for 8 h. RNA was isolated and GCN2, cFOS, and GAPDH steady state
mRNA was measured by qPCR. (Panel B) HepG2-derived clonal cells stably expressing
an inducible shRNA against ATF4 under the control of doxycyclinewere cultured in the ab-
sence (-DOX) or presence (+DOX)of thedrug for 22 days and then incubated in complete
DMEM±His for 8 h. ATF4, cFOS, ASNS, and GAPDH steady state mRNA wasmeasured by
qPCR. For bothpanels the results shownare themeans±SDof assays performed in triplicate.
An asterisk indicates that the shGCN2 value is signiﬁcantly different (p≤ 0.05) than the shCtr
(Panel A) or the + DOX value is different than the - DOX value (Panel B).
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demonstrate that cFOS induction during the AAR is independent of the
classic GCN2-eIF2-ATF4 pathway.
3.4. AAR induction of cFOS is MEK-ERK dependent
cFOS is known to be induced by a wide variety of cellular stresses
that induce one or more of the MAPK pathways [16,19]. The three
major MAPK signaling pathways (MEK-ERK, p38, and JNK) were
screened using chemical inhibitors to identify signaling transduction
leading to cFOS induction following AAR activation. PD98059, which in-
hibits MEK activity, completely blocked cFOS induction during the AAR,
while the JNK inhibitor blocked the induction slightly and inhibition of
p38 activity actually increased cFOSmRNA content following AA limita-
tion (Fig. 5A). A concentration curve for PD98059 inhibition showed
that even at 2.5 μM the MEK inhibitor blocked the AAR-associated in-
crease in cFOS mRNA induction by about 85% (Fig. 5B) and the increase
in p-ERK (Fig. 5C). As an independent method to determine the contri-
bution of MEK-ERK signaling to the regulation of the cFOS gene, ERK1/2
was subjected to knockdown in HepG2 cells using siRNA oligonucleo-
tides (Fig. 5D). Knock down of ERK1/2 caused a signiﬁcant reduction
in the basal (DMEM) and AAR-induced level of cFOS expression. As a
negative control, there was little or no decrease in the induction of the
ATF4-dependent ASNS gene. To further investigate the role of MEK
signaling, MEK deﬁcient HEK293T-ATF4 cells [12], which showed no
signiﬁcant induction of cFOS following AAR activation (Fig. 5E), were
stably transfected with constitutively active MEK (MEKCA). MEKCA ec-
topic expression caused a 10-fold increase in basal cFOS expression
that was further enhanced following AAR activation (Fig. 5E). The
HEK293T-ATF4 cell line used for these studies had been previously
transfected to stably express ATF4 under the control of tetracycline(TET) [28]. Treatment of these cells with TET to induce ATF4 leads to
an induction of ATF4-responsive genes such as ASNS and CHOP [37].
In the present studies, induction of ATF4 caused no change in cFOS in-
duction, with or without MEKCA expression (Fig. 5E). Collectively,
these results provide evidence for the conclusion that cFOS induction
during the AAR is independent of GCN2-ATF4 signaling, but instead is
linked to the MEK-ERK cascade.
3.5. AA deﬁciency induces cFOS through the RAS-RAF-MEK-ERK arm of
MAPK signaling
After establishing that MEK-ERK signaling is required for cFOS in-
duction during the AAR, additional upstream signaling molecules were
investigated. RAF proteins are common regulators of MEK and c-RAF
has been previously shown to induce cFOS expression in response to
numerous stimuli [38,39]. cFOS induction during the AAR was exam-
ined in the presence of the c-RAF inhibitor GW5074, which abolished
cFOS induction in a concentration dependent manner (Fig. 6A). Signal-
ing to c-RAF is often through the RAS family of small GTPases [16,40].
cFOS induction during AAR activation was monitored after suppressing
the expression of individual RAS family members with siRNA (Fig. 6B).
Analysis of the mRNA species for all three RAS forms illustrates
the speciﬁcity of the knock down (Fig. 6C). Knock down of H-RAS or
N-RAS effectively suppressed cFOS induction to levels that were 29%
and 34% respectively, compared to the non-targeting siControl. In
contrast, knock down of K-RAS showed no signiﬁcant effect (Fig. 6B).
Collectively, these results demonstrate that cFOS induction during acti-
vation of the AAR is dependent on the RAS-RAF-MEK-ERK arm of MAPK
signaling.
3.6. The AAR increases cFOS promoter-association of selected transcription
factors and recruits Pol II.
To investigate the role of speciﬁc transcription factors through
which AA-responsive ERK regulates the cFOS gene, two principle pro-
teins known to mediate ERK actions, E-twenty six- like factor 1 (ELK1)
and serum response factor (SRF), were investigated by chromatin im-
munoprecipitation (ChIP). Consistent with the hnRNA analysis indicat-
ing a transcriptional controlmechanism, induction of the AAR increased
the recruitment of RNA Pol II to the cFOS promoter (Fig. 7). Both ELK1
[19,23] and SRF [24] proteins are constitutively bound to the cFOS
gene within the ﬁrst 500 bp upstream of the transcription start site
and in response to speciﬁc stimuli each can be activated by in situ phos-
phorylation. ChIP analysis of HepG2 cells conﬁrmed the constitutive
binding of total ELK1 and SRF in the region of the cFOS proximal pro-
moter, and PCR primers targeted to upstream and downstream regions
across the gene locus illustrated the speciﬁcity of that binding (Fig. 7).
AA limitation did not alter the amount of total ELK1 association and
caused a slight reduction in total SRF bound at the cFOS promoter.
With regard to phosphorylation, the AAR led to a small reduction of p-
SRF likely due to the loss of total SRF. In contrast, therewas a substantial
increase of more than 4-fold in the amount of p-ELK1 associated with
the promoter region (Fig. 7). These results are consistent with the
known signaling of ERK to the cFOS gene through p-ELK1 [41] and indi-
cate that p-ELK1 contributes to the AAR transcriptional program.
3.7. cFOS induction is dependent on the ELK1 transcription factor.
To provide additional evidence that ELK1 is an important factor
in the AA regulation of the EGR1 gene, HepG2 cells were transfected
with a control siRNA or siRNA speciﬁc for ELK1.After activating the
AAR with HisOH treatment for 8 h, the expression of both ELK1
and cFOS was measured (Fig. 8). Consistent with the known mecha-
nism for ELK1 action, phosphorylation of bound ELK1 at the target
gene, the level of ELK1 mRNA was unchanged by the AAR. There
was a strong knock down of ELK1 expression by the speciﬁc siRNA,
Fig. 5. cFOS AAR regulation isMEK-ERK dependent. (Panel A) HepG2 cells were pre-incubated for 1 h in the presence of DMSO (Ctrl), 20 μMPD98059 (-MEK), 10 μMSB203580 (-p38), or
10 μM SP600125 (- JNK). Cells were then incubated in DMEM± His for 8 h, with the inhibitor. cFOS and GAPDH mRNA was measured by qPCR. (Panels B and C) HepG2 cells were pre-
incubated in the presence of DMSO or PD98059 and then incubated inDMEM±His for 8 hwith PD98059. cFOS and GAPDH steady statemRNAwasmeasured by qPCR (Panel B) or p-ERK
and total ERK protein levelswere assayed by immunoblotting (Panel C). (Panel D) HepG2 cells were transiently transfectedwith 100 nMof non-targeting siRNA (Ctrl) or siERK1/2 (50 nM
siERK1+50nMsiERK2) and cultured for 72 h. Cellswere then incubated inDMEM±His for 8 h. ERK, cFOS, ASNS, and GAPDH steady statemRNAwasmeasured by qPCR. The knockdown
of ERK1/2 was conﬁrmed by immunoblotting. (Panel E, upper) HEK293T-ATF4 (Control) or HEK 293 T-ATF4 cells expressing a constitutively active MEK (MEKCA) were incubated in
DMEM, DMEM+ tetracycline (+TET), or DMEM -His for 8 h. The cFOS and GAPDH steady statemRNAwasmeasured by qPCR. (Panel E, lower) The expression of p-ERK and ATF4 protein
was assessed by immunoblotting using total ERK as the loading control. For all mRNA panels, the data shown are the means± SD of assays in triplicate. An asterisk indicates that the ex-
perimental condition is signiﬁcantly different (p ≤ 0.05) from the corresponding control.
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ence of HisOH. These data are consistent with those of Fig. 7
documenting increased phosphorylation of ELK1 at the cFOS gene
and indicate that ELK1 is an important factor in AA-regulated cFOS
expression.
4. Discussion
This study documents the regulation of cFOS induction by AA depri-
vation in HepG2 human hepatocellular carcinoma cells and provides
several novel observations pertaining to the broader topic of AA stress.
1) The data extend a previous observation from an expression array
that cFOS is induced by the AAR [14]. 2) The cFOS induction by AA lim-
itation is primarily due to increased transcription and peaks at 8 h, long
after the well known serum responsiveness of this gene has returned to
the basal state. Furthermore, the AAR associated control does not re-
quire the presence of serum. 3) Activation of the cFOS gene is indepen-
dent of the classic GCN2-eIF2-ATF4 pathway of the AAR. 4) The cFOS
induction requires the RAS-RAF-MEK-ERK arm of MAPK signaling and
MEK-ERK activation is both necessary and sufﬁcient for AAR induction
of cFOS mRNA. 5) The AAR-dependent induction of cFOS transcriptionwas associated with phosphorylation of promoter-bound ELK1 and en-
hanced recruitment of Pol II to the promoter. 6) In contrast to the serum
response for the cFOS gene, phosphorylation of promoter-bound SRF
was not observed.
The GCN2-eIF2-ATF4 pathway is the classic signalingmechanism for
AA limitation that was ﬁrst characterized in yeast, and later document-
ed in mammalian cells [42,43]. GCN2 remains the only well character-
ized sensor of intracellular AA availability, and most of the mammalian
AAR induced genes that have been characterized to date contain a
C/EBP-ATF response element (CARE) that mediates ATF4 activation
[7]. However, an expression array analysis in Gcn2 knockoutmouse em-
bryonic ﬁbroblasts documented a substantial number of AA-responsive
genes that were Gcn2-independent [10]. Subsequently, a growing list
of GCN2- and/or ATF4-independent AAR target genes have been con-
ﬁrmed, including FOXA2/3 [11], cJUN [12], and EGR1 [10,13]. Most of
these examples are linked to activation of one ormore of theMAPKpath-
ways, as has theGCN2-independent pathway leading to phosphorylation
of ATF2 by JNK2 [44]. Collectively, the data emerging from numerous
laboratories indicates that in mammalian cells the GCN2-eIF2-ATF4
pathway is likely a principle mechanism for detecting and responding
to AA limitation, but the AAR is actually a collection of pathways that
Fig. 6. AAR regulation of cFOS is dependent on c-RAF, H-RAS, and N-RAS. (Panel A) HepG2 cells were pre-incubated in the presence of the c-RAF inhibitor GW5074 at the indicated
concentrations and then transferred to complete DMEM or DMEM-His for 8 h, in the continued presence of GW5074. cFOS and GAPDH steady state mRNA was measured by qPCR.
(Panel B) HepG2 cells were transiently transfected with 25 nM of non-targeting siRNA (Ctrl), siRNA against H-RAS (H), siRNA against K-RAS (K), or siRNA against N-RAS (N) and cultured
for 48 h. Cellswere then incubated inDMEM±His for 8 h and then steady statemRNAwasmeasured by qPCR for: cFOS (PanelsA and B); H, K, andNRAS (Panel C); or GAPDH. For all panels,
the results shows are the means ± SD of triplicate assays. An asterisk indicates that the experimental condition is signiﬁcantly different (p ≤ 0.05) from the corresponding control.
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manner.
The induction of cFOS by the AAR is quite different from the induc-
tion of cFOS by growth factors, cytokines, and other extracellular signals
that is can be illustrated by the serum response. First, it does not require
serum or the associated growth factors. Second, transcription is not in-
creased until about 2-4 h after initiating the AAR, well past the time
that the serum-induced activation has returned to the basal state. Final-
ly, induction of the transcriptional activity of the gene itself lasts for at
least 12 h and the steady state mRNA appears to be stabilized for even
longer period of time. All of these observations suggest that the mecha-
nism by which the gene is controlled by intracellular AA supply differs
substantially from that by the growth factors associated with the
serum response. Interestingly, in transformed cells, the normally tran-
sient nature of immediate early response gene expression is sometimes
replaced by amore sustained expression [45]. cFOS is elevated in 30% of
all human cancers, including HCC, but it is rarely directly mutated in
cancer [46]. These observations point to abnormal regulation of up-
stream signaling events as the likely control of cFOS in transformed
cells, a hypothesis consistent with the known elevation of the
MEK-ERK pathway inmany tumors [16,38]. Given the nutrient depriva-
tion and activation of the AAR in tumors [47–49], further activation by
AA deprivation may be superimposed on the high basal level of cFOS.
In this circumstance, nutrient supply may signiﬁcantly impact regula-
tion of cFOS expression.
A number of transcription factors are the terminal effectors for nucle-
ar ERK and among these are SRF and ELK1, which are constitutively
bound to the cFOS promoter and activated by ERK-mediated phosphor-
ylation in situ in a cell and stimulus-speciﬁc manner [19,20,23]. The
present results show that neither total nor phosphorylated SRF associa-
tion with the gene is largely changed by the AAR. In contrast, the totalabundance of constitutively bound ELK1 was unchanged by the AAR,
but the association of p-ELK1with the cFOS promoterwas increased sub-
stantially. These results are consistent with known regulation by ERK-
ELK1 signaling and add further evidence that themechanism of cFOS ac-
tivation by the AAR differs from that the serum response involving p-SRF
[24]. The importance of ELK1 in the AAR control of cFOS was conﬁrmed
by documenting a signiﬁcant reduction of cFOS induction in cells
transfected with siRNA speciﬁc for ELK1.
RAS is typically activated by GDP-GTP exchange following associa-
tionwith adaptor proteins that are linked to plasmamembrane tyrosine
kinase receptors [38,50]. RAF is then recruited to the RAS-containing
complex, increasing its inherent kinase activity. RAF phosphorylates
MEK and thus, triggers the downstream cascade of MEK-ERK-ELK1
[19,20]. The data presented in this report indicates that RAS and RAF
are required for AAR-driven activation of the FOS gene in HepG2 cells.
These data, along with the observation that GCN2 knockdown has no
deleterious effect on FOS induction, strongly suggest that an unknown
amino acid sensor exists and may trigger a step upstream of RAS. All
threemembers of the RAS protein family are homologous and some re-
dundancy is known to occur [51]. However, the results following siRNA
knockdown of each RAS form revealed that both H-RAS and N-RAS
contribute to AAR signaling in HepG2 cells, whereas K-RAS does not.
The reason for this selectivity is not immediately obvious. Despite ex-
tensive research on the RAS proteins, the functional differences are
still not well understood. Examples of such differences that set K-RAS
apart from the other two include the observation that H-RAS and
N-RAS undergo palmitoylation that may regulate the microdomain
localization within the plasma membrane, whereas K-RAS does not
[38]. K-RAS, but not H-RAS and N-RAS, binds calmodulin [51], but
there is no known link between cellular calcium levels and the AAR.
K-RAS deﬁcient mice die during embryogenesis, where as single or
Fig. 7. Transcription factor association with the cFOS promoter in response to the AAR.
(Panel A) The locations of primers (labeled P1-P6) used to analyze the transcription factor
binding to the human cFOS gene are illustrated relative to the transcription start site
(arrow) and the coding region of the gene. The scheme is not drawn to scale. The primer
sequences are listed in Table I. (Panel B) HepG2 cells were incubated in DMEM± His 8 h
and then the cells were subjected to ChIP analysis with antibodies speciﬁc for RNA Pol II,
total SRF, p-SRF, total ELK1, p-ELK1, and a non-speciﬁc IgG as a negative control. The
data are plotted as the ratio to the input DNA and are the averages ± standard deviations
for at least three samples. An asterisk indicates that the DMEM - His value is signiﬁcantly
different (p ≤ 0.05) than the DMEM control.
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members, mutations in K-RAS are by far the most common in human
cancers, but RAS mutations are not highly associated withFig. 8. AAR dependent induction of cFOS is dependent on ELK1. HepG2 cells were
transiently transfected with 100 nM of non-targeting siRNA (Ctrl) or siRNA against ELK1
and cultured for 48 h. Cells were then incubated in DMEM± His for 8 h and then steady
state mRNA was measured by qPCR for ELK1, cFOS, or GAPDH. The results shown are
the means± SD of triplicate assays. An asterisk indicates that the experimental condition
is signiﬁcantly different (p ≤ 0.05) from the corresponding control.hepatocellular carcinomas [51]. Further research will be necessary to
discover the details regarding RAS speciﬁcity within the AAR.
In summary, theAA-dependent transcriptional induction of the cFOS
gene in HepG2 cells occurred via a signaling mechanism that was
independent of the GCN2-eIF2-ATF4 pathway. Evidence for a RAS-
RAF-MEK-ERK-ELK1 cascade was presented illustrating that the collec-
tion of pathways that make up the AAR includes MAPK signaling to
the cFOS gene. As a consequence, the ERK-phosphorylated ETS family
member pELK1must be added to the list of factors thatmediate the reg-
ulatory transcription network of the AAR.
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